(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Crime boss Steven Lyons set to be deported from Bali to Spain- Is Chinese food truly flavorful?
- Understanding Preschool Projects: An Extensive Aide
- Instructions to Floss Appropriately and Forestall Gum Sickness
- They grew up with 'almond moms.' Now, they dread going home for the holidays.
- Netflix's Eddie Murphy documentary explains 'Saturday Night Live' beef: 'That's why I didn't go back for years'
- NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis
- Charli xcx recorded original songs for 'Wuthering Heights' — what to know about the new album for Margot Robbie's film
- An Excursion Through Renowned Western Network programs
